Corporate Spies Feel A Sting

The feds get serious, but is a new law tough enough?

To hear the feds tell it, Kai-Lo Hsu's scheme was every company's worst nightmare. As technical director of Taiwan's Yuen Foong Paper Co., which has been trying to diversify into biotech, Hsu allegedly negotiated for more than a year to get a peek at confidential data about Bristol-Myers Squibb Co.'s blockbuster cancer drug, Taxol. The deal with a man who called himself a "technology-information broker" was to be sealed at a secret June 14 meeting in a suite at Philadelphia's posh Four Seasons Hotel.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.